SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Data in sickle cell disease look encouraging, but a filing is a way away.
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.